Recent ARTL News
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/07/2026 08:18:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:00:10 PM
- Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements • GlobeNewswire Inc. • 04/07/2026 11:50:00 AM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 04/06/2026 04:57:38 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/03/2026 08:46:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:35:26 PM
- Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 03/30/2026 08:46:00 PM
- Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 03/27/2026 02:40:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 03/27/2026 12:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 09:00:13 PM
- Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments • GlobeNewswire Inc. • 03/25/2026 08:05:00 PM
- Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength • GlobeNewswire Inc. • 03/25/2026 11:31:00 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/24/2026 09:33:11 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/24/2026 09:14:06 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/20/2026 09:18:10 PM
- Artelo Biosciences moves into glaucoma research with fully funded clinical study • IH Market News • 03/18/2026 03:00:51 PM
- Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study • GlobeNewswire Inc. • 03/18/2026 12:07:00 PM
- Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients • GlobeNewswire Inc. • 03/18/2026 11:41:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/17/2026 08:45:47 PM
